title: HSP90: chaperone-me-not.
abstract: With increasing understanding of the molecular basis of carcinogenesis, its progression and metastasis, the cancer therapy has shifted from empirical approaches to targeting specific molecules that regulate the complex network of signalling pathways for cell survival and proliferation. These include key players in malignant transformation like protein kinases, transcription factors, steroid hormone receptors, cell cycle regulators, signal transduction proteins and regulators of apoptosis. Almost all these proteins depend upon the molecular chaperone Hsp90 for their proper folding, stability and function and thus are a part of the Hsp90 clientele. Dependence of these proteins on Hsp90 makes this chaperone an appealing target for cancer therapeutics. Inhibition of Hsp90 can affect multiple oncogenic pathways simultaneously. Moreover Hsp90 inhibitors selectively kill cancer cells compared to normal cells and cancer cells have greater dependence on Hsp90 for the maintenance of intracellular protein homeostasis. All this has led to a rapid pace discovery of Hsp90 clients as well as chemical inhibitors of Hsp90. The role of hsp90 in cancer, tumor selectivity of Hsp90 inhibitors and the current status of Hsp90 inhibitors are discussed in the present review.
authors.affiliation: Department of Biotechnology and Bioinformatics, Padmashree Dr D.Y. Patil University, Sector-15, Plot-50, CBD Belapur, Navi Mumbai, India, jyotitope8@gmail.com.
authors.forename: J M
authors.initials: JM
authors.lastname: Patki
authors.forename: S S
authors.initials: SS
authors.lastname: Pawar
mesh_terms: D014408:Biomarkers, Tumor / Q000378:metabolism*; D018841:HSP90 Heat-Shock Proteins / Q000378:metabolism*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy / Q000378:metabolism*
chemical_list: D014408:Biomarkers, Tumor; D018841:HSP90 Heat-Shock Proteins
references.citation: Curr Top Med Chem. 2006;6(11):1205-14
references.pmid: 16842157
references.citation: Cancer Lett. 2004 Apr 8;206(2):149-57
references.pmid: 15013520
references.citation: Blood. 2009 Jan 22;113(4):846-55
references.pmid: 18948577
references.citation: ACS Chem Biol. 2006 Jun 20;1(5):279-84
references.pmid: 17163756
references.citation: Endocr Relat Cancer. 2006 Dec;13 Suppl 1:S125-35
references.pmid: 17259553
references.citation: Mol Cancer Ther. 2003 Jun;2(6):573-80
references.pmid: 12813137
references.citation: Mol Cell Biol. 2007 Jan;27(1):220-8
references.pmid: 17030621
references.citation: Br J Haematol. 2010 Aug;150(4):438-45
references.pmid: 20618337
references.citation: Mol Cancer Ther. 2003 Feb;2(2):131-8
references.pmid: 12589030
references.citation: Biochemistry. 2006 May 2;45(17):5678-85
references.pmid: 16634649
references.citation: ACS Chem Biol. 2008 Oct 17;3(10):645-54
references.pmid: 18785742
references.citation: Cell. 2011 Mar 4;144(5):646-74
references.pmid: 21376230
references.citation: Expert Opin Investig Drugs. 2005 Jun;14(6):569-89
references.pmid: 16004589
references.citation: Chem Biol. 2004 Jun;11(6):787-97
references.pmid: 15217612
references.citation: BMC Cancer. 2011 Oct 31;11:468
references.pmid: 22039910
references.citation: Mini Rev Med Chem. 2009 Feb;9(2):140-52
references.pmid: 19200020
references.citation: Curr Cancer Drug Targets. 2003 Oct;3(5):297-300
references.pmid: 14529382
references.citation: Mol Cell. 2007 Oct 12;28(1):41-56
references.pmid: 17936703
references.citation: Mol Cancer Ther. 2006 May;5(5):1256-64
references.pmid: 16731758
references.citation: Biochem J. 2008 Mar 15;410(3):439-53
references.pmid: 18290764
references.citation: Curr Opin Oncol. 2003 Nov;15(6):419-24
references.pmid: 14624223
references.citation: Mol Pharmacol. 2009 Dec;76(6):1314-22
references.pmid: 19741006
references.citation: Nature. 2003 Sep 25;425(6956):407-10
references.pmid: 14508491
references.citation: Pharmaceuticals (Basel). 2012 Jul 25;5(8):779-801
references.pmid: 24280675
references.citation: J Nucl Med. 2006 May;47(5):793-6
references.pmid: 16644749
references.citation: Trends Mol Med. 2002;8(4 Suppl):S55-61
references.pmid: 11927289
references.citation: FEBS Lett. 2004 Mar 26;562(1-3):11-5
references.pmid: 15069952
references.citation: J Biosci. 2007 Apr;32(3):517-30
references.pmid: 17536171
references.citation: Curr Opin Investig Drugs. 2010 Dec;11(12):1466-76
references.pmid: 21154128
references.citation: Drug Discov Today. 2008 Jan;13(1-2):38-43
references.pmid: 18190862
references.citation: Leukemia. 2008 Aug;22(8):1604-12
references.pmid: 18480838
references.citation: Ann N Y Acad Sci. 2007 Oct;1113:202-16
references.pmid: 17513464
references.citation: Cell Cycle. 2010 May;9(9):1665-6
references.pmid: 20404505
references.citation: Curr Med Chem. 2008;15(26):2702-17
references.pmid: 18991631
references.citation: J Med Chem. 2008 Oct 23;51(20):6495-502
references.pmid: 18816111
references.citation: J Mol Med (Berl). 2004 Aug;82(8):488-99
references.pmid: 15168026
references.citation: Ann Oncol. 2003 Aug;14(8):1169-76
references.pmid: 12881371
references.citation: Ann Oncol. 2008 Mar;19(3):590-4
references.pmid: 18037622
references.citation: ACS Med Chem Lett. 2010 Jan 1;1(1):4-8
references.pmid: 20730035
references.citation: Mol Cancer Ther. 2004 Aug;3(8):1021-30
references.pmid: 15299085
references.citation: Bioorg Med Chem. 2002 Nov;10(11):3555-64
references.pmid: 12213470
references.citation: Exp Cell Res. 1999 Apr 10;248(1):30-43
references.pmid: 10094811
references.citation: J Oncol. 2010;2010:412985
references.pmid: 20628489
references.citation: J Biol Chem. 2008 Jul 4;283(27):18473-7
references.pmid: 18442971
references.citation: Int J Mol Sci. 2011;12(9):5592-603
references.pmid: 22016611
references.citation: Chem Commun (Camb). 2007 Jan 7;(1):22-36
references.pmid: 17279252
references.citation: Drug Discov Today. 2004 Oct 15;9(20):881-8
references.pmid: 15475321
references.citation: Br J Cancer. 1996 Jul;74(2):172-7
references.pmid: 8688318
references.citation: J Org Chem. 2008 Jan 18;73(2):369-73
references.pmid: 18154304
references.citation: Cell. 2000 Jan 7;100(1):57-70
references.pmid: 10647931
references.citation: Drug Resist Updat. 2009 Feb-Apr;12(1-2):17-27
references.pmid: 19179103
references.citation: Pharmaceuticals (Basel). 2011 Oct 25;4(11):1400-1422
references.pmid: 27721330
references.citation: Curr Top Med Chem. 2006;6(11):1163-71
references.pmid: 16842153
references.citation: Clin Biochem. 2009 Nov;42(16-17):1705-12
references.pmid: 19632215
references.citation: Nat Rev Cancer. 2010 Aug;10(8):537-49
references.pmid: 20651736
references.citation: J Med Chem. 2005 Jun 30;48(13):4212-5
references.pmid: 15974572
references.citation: Proc Soc Exp Biol Med. 1998 Apr;217(4):420-34
references.pmid: 9521088
references.citation: Front Biosci (Landmark Ed). 2012 Jun 01;17:2269-77
references.pmid: 22652777
references.citation: Clin Cancer Res. 2012 Jan 1;18(1):64-76
references.pmid: 22215907
references.citation: Drug Discov Today. 2012 Mar;17(5-6):242-52
references.pmid: 22245656
references.citation: Cell. 2008 Apr 4;133(1):38-52
references.pmid: 18394988
references.citation: Oncogene. 1998 May;16(20):2639-45
references.pmid: 9632140
references.citation: J Biol Chem. 2008 Jun 27;283(26):17757-65
references.pmid: 18400751
references.citation: J Org Chem. 2008 Mar 21;73(6):2130-7
references.pmid: 18293999